急性肾损伤是接受检查点抑制剂肿瘤患者死亡的危险因素
该研究纳入2018年3月至2019年5月接受检查点抑制剂(CPI)治疗且随访至2020年4月的759例患者,中位年龄64岁,15.5%发生急性肾损伤(AKI)。年龄和基线肾功能是CPI相关AKI的独立危险因素,而单次AKI发作是死亡的独立危险因素。
要点
- 接受CPI治疗的肿瘤患者中15.5%发生AKI。
- 年龄和基线肾功能是CPI相关AKI的独立危险因素。
- 单次AKI发作是接受CPI治疗患者死亡的独立危险因素。
核心结论
- 15.5%接受免疫治疗的患者发生AKI。
- 单次AKI发作是这些患者死亡的独立危险因素。
- 年龄和基线肾功能是发生AKI的危险因素。
研究设计与样本
- 纳入2018年3月至2019年5月在本中心接受CPI治疗且随访至2020年4月的所有患者。
- 共纳入759例患者,中位年龄64岁,59%为男性,基线中位肌酐0.80 mg/dL。
- AKI根据KDIGO指南定义,采用逻辑回归模型识别AKI独立危险因素,采用actuarial生存分析确定死亡危险因素。
主要发现
- 最常见恶性肿瘤为肺癌,56%接受抗PD-1治疗。
- 随访期间15.5%发生AKI。
- 随访结束时52.3%患者死亡。
- 癌症类型(非黑色素瘤、肺癌或泌尿生殖系统恶性肿瘤)、CPI类型(非CTLA-4、PD-1、PD-L1或其联合)及AKI发作被确定为死亡危险因素。
关键数值与推荐
- AKI定义依据KDIGO指南。
- 年龄和基线肾功能被确定为CPI相关AKI的独立危险因素。
临床怎么用
- 接受CPI治疗的肿瘤患者应关注年龄和基线肾功能以评估AKI风险。
- 发生AKI的CPI治疗患者死亡风险增加,需加强监测和管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Checkpoint inhibitors (CPIs) have drastically improved metastatic cancer outcomes. However, immunotherapy is associated with multiple toxicities, including acute kidney injury (AKI). Data about CPI-related AKI are limited. Our aim was to determine risk factors for CPI-related AKI as well as its clinical characteristics and its impact on mortality in patients undergoing immunotherapy. METHODS: All patients under CPI at our centre between March 2018 and May 2019 and with a follow-up through April 2020 were included. Demographic, clinical and laboratory data were collected. AKI was defined according to the Kidney Disease: Improving Global Outcomes guidelines. We performed a logistic regression model to identify independent risk factors for AKI and actuarial survival analysis to establish risk factors for mortality in this population. RESULTS: A total of 759 patients were included, with a median age of 64 years. A total of 59% were men and baseline median creatinine was 0.80 mg/dL. The most frequent malignancy was lung cancer and 56% were receiving anti-programmed death protein 1 (PD-1). About 15.5% developed AKI during the follow-up. Age and baseline kidney function were identified as independent risk factors for CPI-related AKI. At the end of follow-up, 52.3% of patients had died. The type of cancer (not melanoma, lung or urogenital malignance), type of CPI (not cytotoxic T-lymphocyte-associated protein 4, PD-1, programmed death-ligand 1 or their combination) and the presence of an episode of AKI were identified as risk factors for mortality. CONCLUSIONS: A total of 15.5% of patients under immunotherapy presented with AKI. A single AKI episode was identified as an independent risk factor for mortality in these patients and age and baseline renal function were risk factors for the development of AKI.
引用
- García-Carro C, Bolufer M, Bury R, et al. Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors. Nephrol Dial Transplant. 2022. PMID: 33547795. doi:10.1093/ndt/gfab034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。